ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin
Authors:
- 15 December 2010
- journal article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 37 (6) , 591-600
Abstract
Aim: To investigate the effects of an Aurora kinase B inhibitor (ZM447439) on the cervical cancer cell line SiHa and chemotherapy of cisplatin (cDDP).Materials & Methods: Detected Aurora‐B protein in different tissues of the cervix by immunohistochemistry and then analyzed the relationship between Aurora B protein and clinical parameters of cervical cancer. The effect and synergistic effect of ZM447439 and cDDP on proliferation of SiHa cells was tested by MTT. The changes of cell cycle and apoptosis were detected by flow cytometry. Aurora‐B, histone H3 phosphorylation (H3‐P) protein, human papillomavirus16 E6 (HPV16E6) and BCL‐2, P53, VEGF protein were detected by Western blot.Results: The positive rate of Aurora‐B expression was the highest in cervical cancer and had no significant correlation with clinical stage, lymph node metastasis and age. ZM447439 can reduce the number of SiHa cells, increase the volume of cells and lead to apoptosis. The growth of SiHa cells treated with ZM447439, cDDP and the combination of both was inhibited in dose‐ and time‐dependent manners. The inhibition rate of the combined treatment is significantly higher than that of two other single drug groups (P < 0.05). The synergistic effect is observed in the combined therapy. S‐phase arrest and early apoptosis has become more evident in the combined treatment. ZM447439 significantly inhibited the expression of Aurora‐B and H3‐P protein (P < 0.05). ZM447439, cDDP and the combination of both reduced the expression of HPV16E6 and BCL‐2 protein, raised P53 protein expression (P < 0.05), whose effects were more obvious in the combined therapy. cDDP could also reduce VEGF protein expression, but ZM447439 could not.Conclusion: Our results suggest that Aurora‐B may represent a valid target in cervical squamous carcinoma and has a synergistic effect with cDDP.Keywords
This publication has 22 references indexed in Scilit:
- A High Throughput, Whole Cell Screen for Small Molecule Inhibitors of the Mitotic Spindle Checkpoint Identifies OM137, a Novel Aurora Kinase InhibitorCancer Research, 2009
- Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152The Pharmacogenomics Journal, 2009
- Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cellsExperimental & Molecular Medicine, 2009
- Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cellsJournal of Translational Medicine, 2008
- Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer DetectionJNCI: Journal of the National Cancer Institute, 2008
- A Pentacyclic Aurora Kinase Inhibitor (AKI-001) with High in Vivo Potency and Oral BioavailabilityJournal of Medicinal Chemistry, 2008
- Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomyBritish Journal of Surgery, 2008
- Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomasJournal of Cancer Research and Clinical Oncology, 2007
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Results of a Prospective Randomized Trial with Neoadjuvant Chemotherapy in Stage IB, Bulky, Squamous Carcinoma of the CervixGynecologic Oncology, 1993